Pierre Fabre Strengthens R&D with Acquisition of Global Rights for Cancer Drugs

Pierre Fabre Laboratories, a leading pharmaceutical and dermo-cosmetics company in Europe, has acquired worldwide rights to PFL-721 and PFL-241 from Antares Therapeutics, a spin-out of Scorpion Therapeutics. These drugs are mutant-specific EGFR inhibitors developed to treat non-small cell lung cancer (NSCLC), the most common subtype of lung cancer with EGFR mutations prevalent in 14-38% of tumors, varying by geographic location. The acquisition allows Pierre Fabre to hold global rights and lead clinical development of these promising treatment options addressing significant unmet medical needs. With these additions, Pierre Fabre's R&D portfolio now fully includes other assets such as exarafenib and PFL-002. PFL-721 targets EGFR exon 20 and HER2 exon 20 mutations, while PFL-241, a brain-penetrant 4th-generation inhibitor, focuses on overcoming C797S resistance mutations. The bolstered R&D portfolio resonates with Pierre Fabre's commitment to providing differentiated precision medicine, particularly in therapeutic areas like oncology, rare diseases, and primary care.